Heron Therapeutics (HRTX)

P/S ratio as of April 2025 (TTM): 1.94

According to Heron Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -8.33. At the end of 2024 the company had a P/S ratio of 1.63.

P/S ratio history for Heron Therapeutics from 2001 to 2024

PS ratio at the end of each year

Year	P/S ratio	Change
2024	1.63	-18.64%
2023	2.01	-27.25%
2022	2.76	-74.39%
2021	10.8	-50.56%
2020	21.8	49.97%
2019	14.5	-44.46%
2018	26.2	-30.68%
2017	37.8	-90.59%
2016	401
2015	N/A
2014	N/A
2013	N/A
2012	N/A	-100%
2011	71.2	411.52%
2010	13.9	-65.11%
2009	39.9	13.61%
2008	35.1	34.06%
2007	26.2
2005	7.17	-6.14%
2004	7.64	-26.71%
2003	10.4	181.79%
2002	3.70	-71.51%
2001	13.0

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Alkermes ALKS	2.86	47.09%	🇮🇪 Ireland
Pacira Biosciences PCRX	1.63	-16.23%	🇺🇸 USA
Nektar Therapeutics NKTR	1.20	-38.06%	🇺🇸 USA
Ligand Pharmaceuticals LGND	12.1	522.55%	🇺🇸 USA
SurModics SRDX	3.14	61.74%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Heron Therapeutics (HRTX)

P/S ratio as of April 2025 (TTM): 1.94